Tigecycline for Treatment of Rapidly Growing Mycobacteria

Completed · Phase 2

Conditions studied: Mycobacterium Abscessus Lung Disease, Rapidly Growing Mycobacterial Lung Disease

In brief

To determine the safety, tolerance, and efficacy of Tigecycline when given daily to patients with rapidly growing mycobacterial disease (especially M.abscessus).

Key facts

Study ID

NCT00600600

Run by

The University of Texas Health Science Center at Tyler

People needed

8

Starts

2002-04-01

Expected to finish

2010-12-01

Last updated by the study team

2017-05-23

Who can join

Age: 10 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Positive cultures for rapidly growing mycobacteria
• Patients who have drug resistant isolates or are intolerant of macrolides or have serious infections unresponsive to currently available drugs
• Adults and children 10 years of age and older
• Pretreatment isolate of M. avium complex available for MIC determination
• Available for followup appointments

You may not qualify if…

• History of tetracycline allergy
• If a menstruating female, not pregnant and on adequate birth control

Where it is running

• The University of Texas Health Science Center at Tyler — Tyler, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.